NCT05998824Completed
COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease
Source: ClinicalTrials.gov · Last updated 24 Dec 2024
Brief summary (registry, in English)
The goal of this clinical trial is to test an COVID-19 vaccination information video in adults with sickle cell disease. The main questions it aims to answer are why are some adults with sickle cell disease hesitant to receive COVID-19 vaccination and whether a COVID-19 vaccination information video tailored for people with sickle cell disease will reduce vaccine hesitancy. Participants will complete a brief survey before and after watching a short video with information on vaccine safety, efficacy, and the greater impact of COVID-19 infection on people with sickle cell disease.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 33 (actual)
- First submitted
- 17 Aug 2023
- Start date
- 19 Sept 2023
- Primary completion date
- 30 Sept 2024
- Lead sponsor
- Duke University
- Diseases
- Sickle cell disease
- NCT number
- NCT05998824
What you commit to
- Study type: Interventional
- Participants enrolled: 33
- From 19 Sept 2023 to the primary completion date, 30 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- unable to read or understand spoken English to complete the survey
Who the study is looking for
- diagnosis of sickle cell disease
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke Adult Sickle Cell Program Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.